异钩藤碱对血小板聚集与血栓形成的抑制作用  

Inhibitory effect of Isorhynchophylline on platelet aggregation and thrombosis

作　　者：谢笑龙[1] 吴敏[1] 吴芹[1] 黄燮南[1] 龚其海[1] 石京山[1] 

机构地区：[1]遵义医学院药理学教研室,贵州遵义563000

出　　处：《中国药理学通报》2007年第12期1636-1638,共3页Chinese Pharmacological Bulletin

基　　金：遵义医学院基金资助项目(NoF-166)

摘　　要：目的研究异钩藤碱（isorhynchophylline,Isorhy）对血小板聚集与血栓形成的影响,并探讨其机制。方法以比浊法测定Isorhy体外给药对大鼠血小板聚集的影响;采用动-静脉旁路血栓形成法制作大鼠血栓模型,观察Isorhy对血栓形成的作用;以放免法测定Isorhy对ADP作用下cAMP含量的影响。结果Isorhy0.65mmol·L^-1和1.30mmol·L^-1对ADP（1.5×10^-5mol·L^-1）和凝血酶（thrombin,Thr,3U·ml^-1）诱导的大鼠血小板聚集均有抑制作用（P〈0.01）。静脉注射Isorhy10mg·kg^-1和5mg·kg^-1可明显降低大鼠血栓形成湿重（P〈0.01）。Isorhy0.33-1.30mmol·L^-1可升高ADP作用后的血小板cAMP浓度（P〈0.01）。结论Isorhy明显抑制血小板聚集与大鼠血栓形成,其抗ADP所致血小板聚集的作用机制至少部分地与升高cAMP水平有关。Aim To investigate the effect of Isorhynchophylline （Isorhy） on platelet aggregation or thrombosis, and explore the mechanism of it＇s action. Methods Rat platelet aggregation was determined, cAMP contents were assessed by Born＇s method and radioimmunoassay respectively. The effect of Isorhy on rat＇s thrombosis was observed with the thrombogenesis model of artery-vein bypass. Results Isorhy （0. 65 mmol·L^-1 , 1. 30 mmol·L^-1） was shown to markedly inhibit the rat＇s platelet aggregation induced by ADP or thrombin in a concentration-dependent manner（ P 〈 0. 01 ）. The IC50 of the platelet aggregation induce by ADP and thrombin were 1.60 ± 0. 54 mmol·L^-1 and 1.14 ± 0. 53 mmol·L^-1 respectively. Isorhy 5 mg·kg^-1 and 10 mg·kg^-1 significantly inhibited the rat＇s thrombosis of artery-vein bypass （ P 〈 0. 01 ）. Isorhy 0. 33 - 1.30 mmol·L^-1 markedly increased the intraplatelet cAMP concentration induced by ADP 1.5 × 10^-5 mol·L^-1 （P 〈0.01）. Isorhy 0.33 - 1.30 mmol·L^-1 markedly increased the intraplatelet cAMP concentration induced by ADP 1.5 × 10^-5 mol·L^-1 （P 〈 0. 01 ）, especially in the concentration of 0. 65 mmol·L^-1. Conclusion Isorhy inhibited the platelet aggregation and thrombosis, and the mechanism may partly be due to the increase of intraplatelet cAMP generation.

关 键 词：异钩藤碱 血小板聚集 血栓形成 腺苷环一磷酸 

分 类 号：R-332[医药卫生] R284.1